Please login to the form below

Not currently logged in
Email:
Password:

cardiovascular drug

This page shows the latest cardiovascular drug news and features for those working in and with pharma, biotech and healthcare.

AZ taps Ionis for another drug, this time in NASH

AZ taps Ionis for another drug, this time in NASH

It’s the third time AZ has taken up an option on an Ionis drug under a 2015 alliance in the area of cardiovascular, metabolic and kidney disease, after earlier deals ... for cardiovascular drug AZD8233 and kidney disease candidate AZD2373.

Latest news

  • AZ finally gets EU nod for Veltassa rival Lokelma AZ finally gets EU nod for Veltassa rival Lokelma

    Drug therapy is often modified or discontinued in HF patients as a result, but this can increase the risk of death. ... Björk, who heads up AZ’s cardiovascular, renal and metabolism drug development.

  • Sanofi, Regeneron offer price cut for cholesterol drug Praluent Sanofi, Regeneron offer price cut for cholesterol drug Praluent

    be acceptable for the drug – depending on the patient’s level of risk. ... Amgen - which has been locked in litigation with Sanofi and Regeneron over PCSK9 patent rights - reported positive cardiovascular outcomes data for its drug last year when it

  • J&J seeks US OK to add CV claim to Invokana label J&J seeks US OK to add CV claim to Invokana label

    Johnson &Johnson has moved swiftly ahead with a filing for its diabetes drug Invokana that would include a claim that it can reduce major adverse cardiovascular events (MACE). ... s drug has the most to gain from cardiovascular labelling, threatening

  • FDA rejects Amgen's osteoporosis hope romosozumab FDA rejects Amgen's osteoporosis hope romosozumab

    Last year, the drug hit its main target of reducing vertebral fractures in the FRAME study, but was unable to reduce non-vertebral fracture, a key secondary endpoint. ... on romosozumab than the comparator drug (alendronate) had cardiovascular side

  • Merck & Co's anacetrapib rescued by positive phase III trial Merck & Co's anacetrapib rescued by positive phase III trial

    Merck &Co's anacetrapib rescued by positive phase III trial. Data suggests drug reduces MACE compared to placebo. ... Merck &Co's cardiovascular drug anacetrapib could see a new lease of life after positive results in a phase III trial.

More from news
Approximately 2 fully matching, plus 85 partially matching documents found.

Latest Intelligence

  • Perfecting the pharmaceutical pipeline with AI Perfecting the pharmaceutical pipeline with AI

    For example, a drug being used for cardiovascular disease might be found to have useful qualities for neurological diseases. ... We’re already seeing evidence of how AI can positively impact drug discovery.

  • Going the distance Going the distance

    Looking to the second half of this year and Sanofi is aiming for a Q3 launch for its new PCSK9 cardiovascular disease management drug Praluent (alirocumab), which comes from its collaboration ... centric means that you need to think about your patients

  • Interview: Peter Meeus, Novo Nordisk Interview: Peter Meeus, Novo Nordisk

    Several obstacles stand in the way of the uptake of Tresiba in Europe, including the decision from the US FDA to request more data from Novo Nordisk regarding the drug's ... cardiovascular safety before it can be approved.

  • Pharma deals during October 2012 Pharma deals during October 2012

    In return for granting Merck a global exclusive licence to its cardiovascular drug candidates, Theravance will receive $153m in R&D funding and milestone payments, including a $5m upfront payment and ... 101. Advinus / Takeda. 3 yr discovery,

  • Pharma deals during July 2012 Pharma deals during July 2012

    These are Benlysta (belimumab), an antibody approved for the treatment of lupus; darapladib, a phase III small molecule drug for the treatment of cardiovascular disease; and albiglutide, an albumin-fusion protein ... 168. Vestiq / BioAlliance (a). Licence

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Sanifit appoints Alexander Gold chief medical officer Sanifit appoints Alexander Gold chief medical officer

    Alex arrives here with first class operational and clinical development expertise in novel drug therapies, targeting cardiovascular and metabolic disease and kidney disease amongst others. ... A cardiologist with over 16 years experience of drug

  • Senior AstraZeneca exec jumps ship to small biotech Senior AstraZeneca exec jumps ship to small biotech

    AstraZeneca's chief executive, Pascal Soriot, will take over the job of late-stage drug development on an interim basis, according to news reports. ... Meanwhile Elisabeth Björk, an associate professor of medicine at Uppsala university and leads

  • Milestone names chief medical officer Milestone names chief medical officer

    Cardiovascular specialist Milestone Pharmaceuticals has appointed experienced pharma researcher Dr Francis Plat as its new chief medical officer. ... Milestone's CEO Philippe Douville said: "Dr Plat is the perfect candidate for our development program

  • Jonathan Fox leaves AstraZeneca for MyoKardia Jonathan Fox leaves AstraZeneca for MyoKardia

    He also served for four years as the industry representative to the FDA's Cardiovascular and renal Drug Products Advisory Committee. ... By translating the groundbreaking science of the founding investigators into effective, disease modifying treatments,

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Packer Forbes News November 2015

    A graduate from the University of Bath, Lydia’ s study areas included Cardiovascular Pharmacology, Regenerative Medicine, Drug Targets in the Immune System with her dissertation focusing on the possibility of a

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics